EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease

Hadeel Drweesh, Amal Alotaibi, Hussain Abdalghani Alqassim, Mohammed Mustafa Eid, Shaimaa Abdulhadi Emsaad, Mohamed Omar Saad, Alya Salah Higazy, Abdulrahman Alturaiki, Fares Almutairi, Abdulsattar Alhussain, Abdulmohsen Assiri, Hadeel Alkofide und 3 weitere

Saudi Pharmaceutical Journal · 2026-04 · 34 (2)

DOI: 10.1007/s44446-026-00063-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Pharmaceutical Journal, online erschienen am 17.03.2026. Verfasst von Hadeel Drweesh und 14 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, King Saud University, P. O. Box 2457, 11451, Riyadh, Saudi Arabia. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BiosimilarsClearanceCostsInflammatory bowel diseasePharmacokineticsQatarSaudi Arabia

Autor:innen und Institutionen

  • College of Pharmacy, King Saud University, P. O. Box 2457, 11451, Riyadh, Saudi Arabia.
  • King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
  • King Fahd Specialist Hospital, Dammam, Saudi Arabia.
  • Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
  • Pharmaceutical Care Department, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

Zitieren

APA

Drweesh, H., Alotaibi, A., Alqassim, H. A., Eid, M. M., Emsaad, S. A., Saad, M. O., Higazy, A. S., Alturaiki, A., Almutairi, F., Alhussain, A., Assiri, A., Alkofide, H., Alruthia, Y., Albassam, A., & Alsultan, A. (2026). Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. Saudi Pharmaceutical Journal, 34(2). https://doi.org/10.1007/s44446-026-00063-5

Vancouver

Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, et al. Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. Saudi Pharmaceutical Journal. 2026;34(2). doi:10.1007/s44446-026-00063-5

BibTeX
@article{Drweesh2026,
  author = {Drweesh, Hadeel and Alotaibi, Amal and Alqassim, Hussain Abdalghani and Eid, Mohammed Mustafa and Emsaad, Shaimaa Abdulhadi and Saad, Mohamed Omar and Higazy, Alya Salah and Alturaiki, Abdulrahman and Almutairi, Fares and Alhussain, Abdulsattar and Assiri, Abdulmohsen and Alkofide, Hadeel and Alruthia, Yazeed and Albassam, Ahmed and Alsultan, Abdullah},
  title = {Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease},
  journal = {Saudi Pharmaceutical Journal},
  year = {2026},
  volume = {34},
  number = {2},
  doi = {10.1007/s44446-026-00063-5}
}
Kostenlos starten →